Liver aminotransferases and risk of incident type 2 diabetes: A systematic review and meta-analysis

American Journal of Epidemiology

Volumn 178, Issue 2, 2013, Pages 159-171

  Kunutsor, Setor K ^a,b   Apekey, Tanefa A ^b   Walley, John ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

aminotransferases; liver enzymes; meta analysis; risk; type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

DIABETES; ENZYME ACTIVITY; ERROR ANALYSIS; HEALTH RISK; LITERATURE REVIEW; META-ANALYSIS; RISK FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; EMBASE; HAZARD RATIO; HEALTH SURVEY; HUMAN; INCIDENCE; LIVER; LIVER DISEASE; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PROSPECTIVE STUDY; PUBLICATION; REVIEW; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW;

AMINOTRANSFERASES; LIVER ENZYMES; META-ANALYSIS; RISK; TYPE 2 DIABETES;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; MODELS, STATISTICAL; RISK; WORLD HEALTH;

EID: 84880568311     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws469     Document Type: Review

References (47)

1. Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care. 2009;32(4):741-750.
2. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21(5):732-737. (Pubitemid 28487063)
3. Andre P, Balkau B, Born C, et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes Metab. 2005;31(6):542-550.
4. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City Diabetes Study. Diabetes Care. 2005;28(7):1757-1762. (Pubitemid 40923089)
5. Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28(12):2913-2918. (Pubitemid 43942924)
6. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004;27(6):1427-1432. (Pubitemid 38679993)
7. Kim HC, Kang DR, Nam CM, et al. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea Medical Insurance Corporation Study. Stroke. 2005;36:1642-1647. (Pubitemid 41098755)
8. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136(2):477-485.
9. Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47(8):1360-1369. (Pubitemid 39232420)
10. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(6):1889-1895. (Pubitemid 34564303)
11. Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8(1):25-30. (Pubitemid 351384872)
12. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35(2):373-379. (Pubitemid 34106377)
13. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep. 2008;10(1):73-80.
14. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-967. (Pubitemid 36733754)
15. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. Diabetes. 2001;50(8):1844-1850.
16. Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes. 2004;53(11):2855-2860. (Pubitemid 39425910)
17. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2004;53(10): 2623-2632. (Pubitemid 39299271)
18. Sato KK, Hayashi T, Nakamura Y, et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care. 2008;31(6):1230-1236.
19. Jiamjarasrangsi W, Sangwatanaroj S, Lohsoonthorn V, et al. Increased alanine aminotransferase level and future risk of type 2 diabetes and impaired fasting glucose among the employees in a university hospital in Thailand. Diabetes Metab. 2008; 34(3):283-289.
20. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. JAMA. 2000;283(15):2008- 2012. (Pubitemid 30214957)
21. Chêne G, Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol. 1996;144(6):610-621. (Pubitemid 26304406)
22. Ford ES, Schulze MB, Bergmann MM, et al. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008;31(6):1138-1143.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
24. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135(11):1301-1309.
25. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J. 2006;6(1):40-57. (Pubitemid 43708443)
26. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414): 557-560. (Pubitemid 37088507)
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. (Pubitemid 34746062)
28. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med. 1999;18(20): 2693-2708. (Pubitemid 29481404)
29. Muellerleile P, Mullen B. Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health. 2006;96(3):515-522. (Pubitemid 43320699)
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4): 1088-1101.
31. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634. (Pubitemid 27387172)
32. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455-463. (Pubitemid 30422636)
33. Cho NH, Jang HC, Choi SH, et al. Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. Diabetes Care. 2007;30(10):2566-2568. (Pubitemid 47547795)
34. Goessling W, Massaro JM, Vasan RS, et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135(6): 1935-1944.
35. Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) Study. Metabolism. 2008; 57(3):387-392. (Pubitemid 351178729)
36. Doi Y, Kubo M, Yonemoto K, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama Study. Obesity (Silver Spring). 2007;15(7): 1841-1850. (Pubitemid 47264964)
37. Schindhelm RK, Dekker JM, Nijpels G, et al. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn Study [letter]. Diabetes Care. 2005; 28(11):2812. (Pubitemid 43951189)
38. Kim C-H, Park J-Y, Lee K-U, et al. Association of serum γ-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver. Diabetes Metab Res Rev. 2009;25(1):64-69.
39. Lee D-H, Ha M-H, Kim J-H, et al. Gamma-glutamyltransferase and diabetes - a 4 year follow-up study. Diabetologia. 2003;46(3):359-364. (Pubitemid 36547591)
40. Ohlson LO, Larsson B, Bjorntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31(11): 798-805. (Pubitemid 19004929)
41. Steichen TJ. Nonparametric trim and fill analysis of publication bias in meta-analysis. Stata Tech Bull. 2001; 10(57):8-14.
42. Goto T, Onuma T, Takebe K, et al. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord. 1995; 19(12):841-845. (Pubitemid 26003018)
43. Banerji MA, Buckley MC, Chaiken RL, et al. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord. 1995;19(12):846-850. (Pubitemid 26003019)
44. Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis. 2005;178(2):327-330. (Pubitemid 40193447)
45. Peters JL, Sutton AJ, Jones DR, et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26(25): 4544-4562. (Pubitemid 350020393)
46. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.
47. Danesh J, Erqou S, Walker M, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22(12):839-869.